Vorapaxar in the Secondary Prevention of Atherothrombotic Events

Morrow, David A. M.D., M.P.H.
Braunwald, Eugene M.D.
Bonaca, Marc P. M.D.
Ameriso, Sebastian F. M.D.
Dalby, Anthony J. M.B., Ch.B.
Fish, Mary Polly B.A.
Fox, Keith A.A. M.B., Ch.B.
Lipka, Leslie J. M.D., Ph.D.
Liu, Xuan Ph.D.
Nicolau, José Carlos M.D., Ph.D.
Ophuis, Oude A.J. M.D., Ph.D.
Paolasso, Ernesto M.D.
Scirica, Benjamin M. M.D., M.P.H.
Spinar, Jindrich M.D., Ph.D.
Theroux, Pierre C.M., M.D.
Wiviott, Stephen D. M.D.
Strony, John M.D.
Murphy, Sabina A. M.P.H.

The authors' affiliations are listed in the Appendix. Address reprint requests to Dr. Morrow at the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at [email protected]

^*Members of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P)-Thrombolysis in Myocardial Infarction (TIMI) 50 steering committee, as well as other committee members and investigators, are listed in the Supplementary Appendix, available at NEJM.org.

This article (10.1056/NEJMoa1200933) was published on March 24, 2012, at NEJM.org.

Supported by Merck.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

New England Journal of Medicine 366(15):p 1404-1413, April 12, 2012.